Literature DB >> 12023324

Striatal and extrastriatal dysfunction in Parkinson's disease with dementia: a 6-[18F]fluoro-L-dopa PET study.

Kengo Ito1, Atsuko Nagano-Saito, Takashi Kato, Yutaka Arahata, Akinori Nakamura, Yasuhiro Kawasumi, Kentaro Hatano, Yuji Abe, Takako Yamada, Teruhiko Kachi, David J Brooks.   

Abstract

We investigated the relative differences in dopaminergic function through the whole brain in patients with Parkinson's disease without dementia (PD) and with dementia (PDD) using 6-[18F]fluoro-L-dopa (18F-dopa) PET and a voxel-by-voxel analysis. The 10 PD and 10 PDD patients were equivalently disabled, having mean scores of 3.2 +/- 0.6 and 3.2 +/- 0.7, respectively, on the Hoehn and Yahr rating scale. 18F-dopa influx constant (Ki) images of those patients and 15 normal age-matched subjects were transformed into standard stereotactic space. The significant differences between the groups (expressed in mean regional Ki values) were localized with statistical parametric mapping (SPM) on a voxel-by-voxel basis. Compared with the normal group, SPM localized declines of the 18F-dopa Ki bilaterally in the putamen, the right caudate nucleus and the left ventral midbrain for the PD group (P < 0.01, corrected). Compared with the normal group, the PDD group showed reduced 18F-dopa Ki bilaterally in the striatum, midbrain and anterior cingulate area (P < 0.01, corrected). A relative difference in 18F-dopa uptake between PD and PDD was the bilateral decline in the anterior cingulate area and ventral striatum and in the right caudate nucleus in the PDD group (P < 0.001, corrected). Accordingly, we conclude that dementia in PD is associated with impaired mesolimbic and caudate dopaminergic function.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12023324     DOI: 10.1093/brain/awf134

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  36 in total

1.  T1rho (T1ρ) MR imaging in Alzheimer's disease and Parkinson's disease with and without dementia.

Authors:  Mohammad Haris; Anup Singh; Kejia Cai; Christos Davatzikos; John Q Trojanowski; Elias R Melhem; Christopher M Clark; Arijitt Borthakur
Journal:  J Neurol       Date:  2010-10-07       Impact factor: 4.849

Review 2.  Neuroimaging and cognition in Parkinson's disease dementia.

Authors:  Lisa C Silbert; Jeffrey Kaye
Journal:  Brain Pathol       Date:  2010-05       Impact factor: 6.508

Review 3.  Biomarkers for cognitive impairment in Parkinson disease.

Authors:  Min Shi; Bertrand R Huber; Jing Zhang
Journal:  Brain Pathol       Date:  2010-05       Impact factor: 6.508

4.  Motivational engagement in Parkinson's disease: Preparation for motivated action.

Authors:  J B Renfroe; M M Bradley; M S Okun; D Bowers
Journal:  Int J Psychophysiol       Date:  2015-12-01       Impact factor: 2.997

5.  Parkinson's disease-related spatial covariance pattern identified with resting-state functional MRI.

Authors:  Tao Wu; Yilong Ma; Zheng Zheng; Shichun Peng; Xiaoli Wu; David Eidelberg; Piu Chan
Journal:  J Cereb Blood Flow Metab       Date:  2015-06-03       Impact factor: 6.200

6.  Regional changes in the type 1 cannabinoid receptor are associated with cognitive dysfunction in Parkinson's disease.

Authors:  Jenny Ceccarini; Cindy Casteels; Rawaha Ahmad; Melissa Crabbé; Laura Van de Vliet; Heleen Vanhaute; Mathieu Vandenbulcke; Wim Vandenberghe; Koen Van Laere
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-07-24       Impact factor: 9.236

7.  Dementia in long-term Parkinson's disease patients: a multicentre retrospective study.

Authors:  Jennifer Y Y Szeto; Courtney C Walton; Alexandra Rizos; Pablo Martinez-Martin; Glenda M Halliday; Sharon L Naismith; K Ray Chaudhuri; Simon J G Lewis
Journal:  NPJ Parkinsons Dis       Date:  2020-01-07

Review 8.  Cognitive decline in Parkinson disease.

Authors:  Dag Aarsland; Byron Creese; Marios Politis; K Ray Chaudhuri; Dominic H Ffytche; Daniel Weintraub; Clive Ballard
Journal:  Nat Rev Neurol       Date:  2017-03-03       Impact factor: 42.937

Review 9.  Mesencephalic and extramesencephalic dopaminergic systems in Parkinson's disease.

Authors:  Fanni F Geibl; Martin T Henrich; Wolfgang H Oertel
Journal:  J Neural Transm (Vienna)       Date:  2019-01-14       Impact factor: 3.575

10.  Recent imaging advances in the diagnosis and management of Parkinson's disease.

Authors:  David J Brooks; Nicola Pavese
Journal:  F1000 Med Rep       Date:  2009-10-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.